Please ensure Javascript is enabled for purposes of website accessibility

Gilead Sciences Expands Access to Experimental COVID-19 Treatment

By Cory Renauer - Mar 29, 2020 at 11:38AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company developing remdesivir to treat the novel coronavirus has a new program to deal with a flood of compassionate use requests.

An experimental treatment could become easier to get a hold of for hospitals with increasing numbers of COVID-19 patients. Gilead Sciences, (GILD -1.32%) a biopharmaceutical company, has already started ramping up approvals of applications for emergency use of an experimental coronavirus treatment called remdesivir. 

Expanded access 

The Food and Drug Administration (FDA) already has an expanded access program for experimental drugs that's more commonly known as the "compassionate use" program. Unfortunately, the compassionate use program isn't set up to handle a flood of requests that have been growing exponentially.

Doctor in a facemask.

Image source: Getty Images.

To access a drug in clinical trials that hasn't been approved yet, patients and their physicians need to show ineligibility for those trials. If a patient can cross this hurdle, they still need the company to submit an expanded access request to the FDA, which is the part of the process that Gilead will accelerate.

Instead of approving one application at a time, the company will streamline its approach and allow physicians and hospitals to apply for emergency use of remdesivir for multiple patients at once.

Next steps  

Unfortunately, healthcare providers and their COVID-19 patients might not see a significant increase in access to remdesivir. Gilead may be willing to process group applications, but there are still two roadblocks that might not be as flexible.

Gilead can streamline group applications for expanded access, but those applications still need to be reviewed by an investigational review board (IRB). Once an IRB concludes the patient knows what they're getting into, the FDA finally reviews the expanded access request.

Cory Renauer owns shares of Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$61.09 (-1.32%) $0.82

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.